Pendulum: Revolutionizing gut health through science and innovation
Clinically-studied, proprietary strains designed to transform health through the gut microbiome.*
.png%3F2025-10-07T18%3A22%3A25.841Z&w=3840&q=100)
Reimagine the health of your patients by targeting the gut microbiome
Using cutting-edge technology and microbiome science, Pendulum was the first company in the US to market live Akkermansia muciniphila. Akkermansia supports the synthesis of health-promoting postbioitics and strengthens gut barrier integrity.*
Pendulum’s Akkermansia-containing formulations have been clinically studied and published in the British Medical Journal. Improving gut barrier function and maintaining healthy blood sugar levels with Pendulum’s strains is a foundational way to help your patients find optimal health by harnessing the power of the gut microbiome.^*
.jpg%3F2025-10-07T18%3A35%3A23.016Z&w=3840&q=100)
Join the 15,000+ practitioners recommending Pendulum Akkermansia
Akkermansia 100 Pro
Maintain keystone strain levels Regular strength live Akkermansia muciniphila helps maintain gut health, supports the gut lining, and manages gut permeability.*
Akkermansia 500 Pro
Replenish keystone strain levels Maximum strength live Akkermansia muciniphila—ideal for patients with advanced indications of intestinal barrier permeability, replenishing this critical strain for optimal gut health.*
Get to know the products
Fullscript and Pendulum provider survey with Akkermansia 500 Pro
Will continue to recommend Akkermansia 500 Pro**
Would recommend Akkermansia 500 Pro to other health care providers**
Study
How providers are using a GLP-1 probiotic in clinical practice
In survey conducted in 2024 of healthcare providers who use a GLP-1 Probiotic
- 97% of healthcare providers recommend as a way to manage food cravings+
- 78% Recommend as a strategy to help patients transition off of GLP-1 medications, specifically to help manage food cravings associated with this transition+
- 64% Recommend as a first line approach before prescribing a GLP-1 medication+
- 53% Recommend in combination with GLP-1 medications+
Resources for your practice
Fullscript accounts are $0/month — for everyone
Get your practice and patients up and running quickly at no cost.
^ Based on preclinical studies
1, 2 Based on a multicenter, double-blind, randomized placebo-controlled trial
3 Improvements to postprandial glucose control in subjects with type 2 diabetes: a multicenter, double blind, randomized placebo-controlled trial of a novel probiotic formulation, Fanny Perraudeau et al, https://drc.bmj.com/content/8/1/e001319
**Survey results from 82 providers who recommended or purchased Akkermansia 500 million AFU between January-July 2024 on Fullscript.
+Based on a survey conducted internally in 2024 of 64 healthcare providers
